Overview
- Editors:
-
-
Zbigniew Petrovich
-
Department of Radiation Oncology, University of Southern California, USC/Norris Cancer Center, Los Angeles, USA
-
Luc Baert
-
Department of Urology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium
-
Luther W. Brady
-
Department of Radiation Oncology and Nuclear Medicine, Allegheny University Hospitals, Center City, Philadelphia, USA
Access this book
Other ways to access
Table of contents (29 chapters)
-
- F. Calabrò, C. N. Sternberg
Pages 221-233
-
- M. Rotman, H. Aziz, D. Schwartz, J. Cirrone, A. Schulsinger, K. Choi et al.
Pages 235-241
-
-
-
- B. H. Bochner, S. D. Boyd
Pages 259-265
-
- B. J. Costleigh, W. A. Longton, L. W. Brady, C. T. Miyamoto, J. E. Friere, B. Micaily et al.
Pages 268-278
-
- D. J. M. K. De Ridder, J. E. Binard, L. Baert
Pages 279-285
-
- H Goethuys, L. Baert, Z. Petrovich
Pages 287-295
-
- C. C. D. Van Der Rijt, T. A. W. Splinter
Pages 297-308
-
-
Back Matter
Pages 317-328
About this book
Bladder cancer represents a major challenge to the oncologist. In spite of new tech niques for early diagnosis and innovative imaging procedures for staging, the outcome in terms of cure has not improved during the past ten years. Fortunately, about 74% of the patients present with localized disease, with 18% presenting with localized and regional disease, and 3% with distant metastases at diagnosis. In accordance with the stage at presentation, 94% of patients with localized disease are controlled at 5 years, as are 50% of patients with local and regional disease but un fortunately only 7% of those with distant disease. The survival data for Afro-Americans are more grave, with only 79% of patients with localized disease surviving at 5 years, 38% with local and regional disease, and 4% with disseminated disease. Even after 5 years, however, patients continue to fail not only locally and regionally but also with disseminated disease, thereby creating enigmas as to the continued influence of basic molecular changes, basic etiologic agents, and unsuspected more advanced disease, as well as demonstrating the inadequacies of local surgical treatment programs. These factors have led to braoder programs of combined integrated multimodal treatment earlier in the course of the disease process. Clearly, these newer innovative programs have placed increasing emphasis on the combination of surgery with radiation therapy and chemotherapy.
Editors and Affiliations
-
Department of Radiation Oncology, University of Southern California, USC/Norris Cancer Center, Los Angeles, USA
Zbigniew Petrovich
-
Department of Urology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium
Luc Baert
-
Department of Radiation Oncology and Nuclear Medicine, Allegheny University Hospitals, Center City, Philadelphia, USA
Luther W. Brady